isatuximab


( Last Updated : July 30, 2021)
Generic Name:
isatuximab
Project Status:
Active
Therapeutic Area:
Multiple myeloma
Call for patient/clinician input open:
Brand Name:
Sarclisa
Project Line:
Reimbursement Review
Project Number:
PC0256-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
In combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
Myeloma
Indications:
In combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openJune 16, 2021
Call for patient/clinician input closedAugust 09, 2021
Submission receivedJuly 15, 2021
Submission acceptedJuly 29, 2021
Review initiatedJuly 30, 2021
Draft CADTH review report(s) provided to sponsor for commentOctober 15, 2021
Deadline for sponsors commentsOctober 26, 2021
CADTH review report(s) and responses to comments provided to sponsorNovember 19, 2021
Expert committee meeting (initial)December 01, 2021
Draft recommendation issued to sponsorDecember 13, 2021
To
December 15, 2021
Draft recommendation posted for stakeholder feedback
End of feedback period